A Targeted Multi-Crystalline Manganese Oxide as a Tumor-Selective Nano-Sized MRI Contrast Agent for Early and Accurate Diagnosis of Tumors
Gongxin Yang,Jikai Xia,Xiaoqing Dai,Hongbo Zhao,Weiqing Gao,Weilong Ding,Xiaofeng Tao,Ling Zhu
DOI: https://doi.org/10.2147/ijn.s444061
IF: 7.033
2024-01-19
International Journal of Nanomedicine
Abstract:Gongxin Yang, 1, &ast Jikai Xia, 2, &ast Xiaoqing Dai, 1, &ast Hongbo Zhao, 1 Weiqing Gao, 1 Weilong Ding, 1 Xiaofeng Tao, 1 Ling Zhu 1 1 Department of Radiology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, 200001, People's Republic of China; 2 Department of Radiology, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, Shandong, 264100, People's Republic of China &astThese authors contributed equally to this work Correspondence: Xiaofeng Tao; Ling Zhu, Department of Radiology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, 200001, People's Republic of China, Email ; Introduction: Magnetic resonance imaging (MRI) is an important tool for the accurate diagnosis of malignant tumors in clinical settings. However, the lack of tumor-specific MRI contrast agents limits diagnostic accuracy. Methods: Herein, we developed αv integrin receptor-targeting multi-crystalline manganese oxide (MCMO) as a novel MRI contrast agent for accurate diagnosis of tumors by coupling iRGD cyclopeptide PEGylation polymer onto the surface of MCMO (iRGD-pMCMO). Results: The MCMO consisted of numerous small crystals and exhibited an oval structure of 200 nm in size. The iRGD-pMCMO actively recognizes tumor cells and effectively accumulates at the tumor site, consequently releasing abundant Mn 2+ ions in a weakly acidic and high-GSH-expressing tumor microenvironment. Subsequently, Mn 2+ ions interact with cellular GSH to form Mn-GSH chelates, enabling efficient T 1 -weighted MR contrast imaging. In vivo experiments indicated that iRGD-pMCMO significantly improved T 1 -weighted images, achieving an accurate diagnosis of subcutaneous and orthotopic tumors. The results verified that the T 1 contrast effect of iRGD-pMCMO was closely associated with the expression of GSH in tumor cells. Conclusion: Altogether, the novel tumor-targeting, highly sensitive MRI contrast agent developed in this study can improve the accuracy of MRI for tumor diagnosis. Keywords: multi-crystalline manganese oxide, MRI contrast agent, tumor targeting, tumor selectivity, accurate diagnosis Graphical As a clinical diagnostic tool, magnetic resonance imaging (MRI) offers several advantages, such as non-ionizing radiation, non-invasiveness, and assessment of functional information of diseased tissues. 1–3 MRI primarily utilizes the changes in the signal of hydrogen (H) protons to generate images of tissues. 4,5 Therefore, it has a high sensitivity for diagnosing soft tissue diseases, especially malignant tumors. MRI contrast agents (MRICAs) are usually used to improve the distinction between normal and tumor tissues. 6–8 MRICAs are developed mainly based on paramagnetic gadolinium (Gd) and manganese complexes that have long electronic relaxation durations and abundant unpaired electrons. 9,10 The Food and Drug Administration (FDA) has approved the use of magnetic iron oxide as a T 2 MRICA; however, gadolinium (Gd)- and manganese (Mn)-based T 1 MRICAs are predominantly used in clinical settings. 11–13 Moreover, the majority of clinical MRICAs are non-targeted small molecules that readily enter the intravascular and interstitial spaces of normal tissues, resulting in an inaccurate diagnosis of tumors. The emergence of tumor-selective MRICAs has introduced novel avenues for improving the MRI diagnostic accuracy of tumors. Two strategies are primarily used for developing tumor-selective MRICAs: (1) Labeling the target ligand onto the surface of MRICAs; (2) Developing tumor microenvironment (TME)-responsive MRICAs. For highly efficient imaging, MRICAs should have strong attenuation effects on the T 1 or T 2 relaxation time of H protons. As T 1 MRICAs, individual Gd or manganese chelates have relatively weak attenuation effects on T 1 relaxation time, 14 resulting in low contrast enhancement. Gd chelates, such as Gd-DTPA, have been reported to cause nephrotoxic effects and accumulate in the brain in clinical settings. 15,16 These harmful effects limit the applicability of Gd-based MRICAs. Manganese is an essential trace element for maintaining various life activities; 17 therefore, manganese complexes such as MRICAs may have a better biosafety profile than Gd complexes. Developing novel nanoplatforms that accommodate a high payload of manganese ions can effectively improve the contrast of individual manganese chelates. In re -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology